Coronavirus company news summary – US DOD selects Pharm-Olam to support Operation Warp Speed vaccine trials

24 September 2020 (Last Updated September 24th, 2020 10:12)

24 September

Chief Pentagon spokesman Jonathan Hoffman has issued a statement on the report regarding the use of Defense Production Act (DPA) Title III funding. The Washington Post reported that the Defense Department used portions of the Covid-19 funding for buying military equipment instead of medical supplies. Hoffman said: “The CARES Act did not limit - nor did it intend to limit in its language - the use of Defense Production Act (DPA) Title III to only medical resources. As part of the efforts to mitigate economic damage, the Act allowed monies to be spent to support individuals and industries that had been impacted by Covid. This is exactly what DOD has done.”

The US Department of Defense (DOD) has selected clinical research organisation (CRO) Pharm-Olam to support Operation Warp Speed vaccine trials. The company will collaborate with The Geneva Foundation (Geneva) to provide project management, contract management, and clinical trial site support to operational trials at military treatment facilities that are participating in the rapid development of Covid-19 vaccines.

US Naval Surface Warfare Center, Crane Division (NSWC Crane) has agreed to licence and loan its sensor agnostic thermal imaging system for Covid-19 screening at Greene County General Hospital (GCGH). The technology is being provided under a new Cooperative Research and Development Agreement (CRADA). NSWC Crane will install the required equipment for a trial at GCGH. The system is designed to detect fevers on individuals and moving crowds every 0.016 seconds in near real-time. It is capable of working from a distance of around 200 yards.